Arcot Systems

Arcturus Therapeutics is a late-stage clinical biopharmaceutical company focused on the development of innovative RNA medicines for rare diseases and infectious disease vaccines. The company leverages its proprietary LUNAR® lipid-mediated delivery platform and STARR® self-amplifying mRNA (sa-mRNA) technology to create highly potent and durable therapeutic candidates. Its lead programs include a commercially approved COVID-19 vaccine in Japan (ARCT-154) and clinical-stage candidates for Ornithine Transcarbamylase (OTC) deficiency and Cystic Fibrosis. Arcturus has established strategic partnerships with global healthcare leaders, including CSL Seqirus and Meiji Seika Pharma, to accelerate the global distribution of its mRNA-based solutions.